PEPTIDES DERIVED FROM THE D1-DOMAIN OF NKP46

Angel Porgador (Inventor)

Research output: Patent

Abstract

The invention relates to use of specific peptides derived from the cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. The invention further relates to compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
Original languageEnglish
Patent numberEP2828291
IPCC07K 14/ 705 A I
Priority date14/03/13
StatePublished - 28 Jan 2015

Fingerprint

Dive into the research topics of 'PEPTIDES DERIVED FROM THE D1-DOMAIN OF NKP46'. Together they form a unique fingerprint.

Cite this